Baxter International stock slipped 2.1% to about US$23 after releasing Q3 2026 results, extending a weak 3 month stretch for the shares. The headline story looks very different from that price move. The medical products group just posted roughly US$3.0b in quarterly revenue with adjusted earnings per share of about US$0.58 and lifted full year organic sales and EPS guidance.

Short term traders see a tired chart. Long term investors see a healthcare supplier trying to turn years of losses and a stretched balance sheet into a cleaner, cash focused story over the next few years.

Like the Baxter International turnaround story but want cleaner balance sheets without years of legacy issues attached? Screen for companies that pair steady…